TY - THES AU - Földi, Mátyás Csaba TI - A riluzol hatásmechanizmusának vizsgálata fotoaktiválható riluzol analóg segítségével PY - 2022 SP - 87 UR - https://m2.mtmt.hu/api/publication/33628903 ID - 33628903 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Hackl, Benjamin AU - Lukács, Péter AU - Ebner, Janine AU - Pesti, Krisztina AU - Haechl, Nicholas AU - Földi, Mátyás Csaba AU - Lilliu, Elena AU - Schicker, Klaus AU - Kubista, Helmut AU - Stary-Weinzinger, Anna AU - Hilber, Karlheinz AU - Mike, Árpád AU - Todt, Hannes AU - Koenig, Xaver TI - The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 13 PY - 2022 PG - 15 SN - 1663-9812 DO - 10.3389/fphar.2022.809802 UR - https://m2.mtmt.hu/api/publication/32801600 ID - 32801600 N1 - Department of Neurophysiology and Neuropharmacology, Medical University of Vienna, Vienna, Austria ELKH, Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary Department of Biochemistry, ELTE Eötvös Loránd University, Budapest, Hungary Semmelweis University, School of Ph.D. Studies, Budapest, Hungary Department of Pharmacology and Toxicology, University of Vienna, Vienna, Austria Cited By :1 Export Date: 24 October 2022 Correspondence Address: Koenig, X.; Department of Neurophysiology and Neuropharmacology, Austria; email: xaver.koenig@meduniwien.ac.at Chemicals/CAS: ivabradine, 148849-67-6, 148870-80-8, 155974-00-8 Manufacturers: Sigma Aldrich LA - English DB - MTMT ER - TY - JOUR AU - Mike, Árpád AU - Pesti, Krisztina AU - Földi, Mátyás Csaba AU - Tóth, Ádám Viktor AU - Zboray, Katalin AU - Lukács, Péter TI - Automated patch-clamp with automated analysis: extracting compound-specific, concentration-independent biophysical properties of inhibition for sodium channel inhibitors JF - BIOPHYSICAL JOURNAL J2 - BIOPHYS J VL - 121 PY - 2022 IS - 3 Suppl. 1 SP - 92 EP - 92 PG - 1 SN - 0006-3495 DO - 10.1016/j.bpj.2021.11.2238 UR - https://m2.mtmt.hu/api/publication/32676587 ID - 32676587 LA - English DB - MTMT ER - TY - JOUR AU - Lukács, Péter AU - Pesti, Krisztina AU - Földi, Mátyás Csaba AU - Zboray, Katalin AU - Tóth, Ádám Viktor AU - Papp, Gábor AU - Mike, Árpád TI - An Advanced Automated Patch Clamp Protocol Design to Investigate Drug—Ion Channel Binding Dynamics JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 12 PY - 2021 PG - 14 SN - 1663-9812 DO - 10.3389/fphar.2021.738260 UR - https://m2.mtmt.hu/api/publication/32468284 ID - 32468284 N1 - Funding Agency and Grant Number: Hungarian Brain Research Program Funding text: Funding This work was supported by the Hungarian Brain Research Program (KTIA-NAP-1322014002), and by Hungarys Economic Development, and Innovation Operative Programme (GINOP-2.3.2-15-2016-00051). LA - English DB - MTMT ER - TY - JOUR AU - Pesti, Krisztina AU - Földi, Mátyás Csaba AU - Zboray, Katalin AU - Tóth, Ádám Viktor AU - Lukács, Péter AU - Mike, Árpád TI - Characterization of Compound-Specific, Concentration-Independent Biophysical Properties of Sodium Channel Inhibitor Mechanism of Action Using Automated Patch-Clamp Electrophysiology JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 12 PY - 2021 PG - 13 SN - 1663-9812 DO - 10.3389/fphar.2021.738460 UR - https://m2.mtmt.hu/api/publication/32218209 ID - 32218209 N1 - Összes idézések száma a WoS-ban: 0 LA - English DB - MTMT ER - TY - JOUR AU - Földi, Mátyás Csaba AU - Pesti, Krisztina AU - Zboray, Katalin AU - Tóth, Ádám Viktor AU - Hegedűs, Tamás AU - Málnási Csizmadia, András AU - Lukács, Péter AU - Mike, Árpád TI - The mechanism of non-blocking inhibition of sodium channels revealed by conformation-selective photolabeling JF - BRITISH JOURNAL OF PHARMACOLOGY J2 - BR J PHARMACOL VL - 178 PY - 2021 IS - 5 SP - 1200 EP - 1217 PG - 18 SN - 0007-1188 DO - 10.1111/bph.15365 UR - https://m2.mtmt.hu/api/publication/31821613 ID - 31821613 N1 - MTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary School of PhD Studies, Semmelweis University, Budapest, Hungary Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary Motor Pharmacology Research Group, Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary Export Date: 20 March 2021 CODEN: BJPCB Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology GroupHungary; email: arpadmike1@gmail.com Correspondence Address: Mike, A.; Plant Protection Institute, Hungary; email: arpadmike1@gmail.com Correspondence Address: Mike, A.; Department of Biochemistry, Hungary; email: arpadmike1@gmail.com Funding details: KTIA‐NAP‐13‐2‐2014‐002 Funding details: GINOP‐2.3.2‐15‐2016‐00051 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, K127961 Funding text 1: This work was supported by the Hungarian Brain Research Program (KTIA‐NAP‐13‐2‐2014‐002), Hungary's Economic Development and Innovation Operative Programme (GINOP‐2.3.2‐15‐2016‐00051), NKFIH K127961, and the Semmelweis Science and Innovation Fund. MTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary School of PhD Studies, Semmelweis University, Budapest, Hungary Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary Motor Pharmacology Research Group, Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary Export Date: 26 April 2021 CODEN: BJPCB Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology GroupHungary; email: arpadmike1@gmail.com Correspondence Address: Mike, A.; Plant Protection Institute, Hungary; email: arpadmike1@gmail.com Correspondence Address: Mike, A.; Department of Biochemistry, Hungary; email: arpadmike1@gmail.com Funding details: KTIA‐NAP‐13‐2‐2014‐002 Funding details: GINOP‐2.3.2‐15‐2016‐00051 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, K127961 Funding text 1: This work was supported by the Hungarian Brain Research Program (KTIA‐NAP‐13‐2‐2014‐002), Hungary's Economic Development and Innovation Operative Programme (GINOP‐2.3.2‐15‐2016‐00051), NKFIH K127961, and the Semmelweis Science and Innovation Fund. AB - Sodium channel inhibitors can be used to treat hyperexcitability-related diseases, including epilepsies, pain syndromes, neuromuscular disorders, and cardiac arrhythmias. The applicability of these drugs is limited by their nonspecific effect on physiological function. They act mainly by sodium channel block and in addition by modulation of channel kinetics. While channel block inhibits healthy and pathological tissue equally, modulation can preferentially inhibit pathological activity. An ideal drug designed to target the sodium channels of pathological tissue would act predominantly by modulation. Thus far, no such drug has been described.Patch-clamp experiments with ultra-fast solution exchange and photolabeling-coupled electrophysiology were applied to describe the unique mechanism of riluzole on Nav1.4 sodium channels. In silico docking experiments were used to study the molecular details of binding.We present evidence that riluzole acts predominantly by non-blocking modulation. We propose that, being a relatively small molecule, riluzole is able to stay bound to the binding site, but nonetheless stay off the conduction pathway, by residing in one of the fenestrations. We demonstrate how this mechanism can be recognized.Our results identify riluzole as the prototype of this new class of sodium channel inhibitors. Drugs of this class are expected to selectively prevent hyperexcitability, while having minimal effect on cells firing at a normal rate from a normal resting potential. LA - English DB - MTMT ER - TY - JOUR AU - Miskolczi, Tímea Dóra AU - Zboray, Katalin AU - Keszőcze, Anikó Zsófia AU - Quddoos, Zainab AU - Ambrózy, Zsuzsanna AU - Hamow, Kamirán Áron AU - Tóth, Ádám Viktor AU - Sági, László AU - Szelényi, Magdolna Olívia AU - Radványi, Dalma AU - Földi, Mátyás Csaba AU - Molnár, Béla Péter AU - Pesti, Krisztina AU - Mike, Árpád AU - Lukács, Péter TI - Development of a Smell Biosensor System for Early Detection of Plant Diseases JF - BIOPHYSICAL JOURNAL J2 - BIOPHYS J VL - 118 PY - 2020 IS - 3 Suppl. 1 SP - 315A EP - 315A PG - 1 SN - 0006-3495 DO - 10.1016/j.bpj.2019.11.1774 UR - https://m2.mtmt.hu/api/publication/31180515 ID - 31180515 LA - English DB - MTMT ER - TY - JOUR AU - Földi, Mátyás Csaba AU - Lukács, Péter AU - Pesti, Krisztina AU - Málnási Csizmadia, András AU - Mike, Árpád TI - Riluzole as a Prototype of a New Class of Sodium Channel Inhibitors JF - BIOPHYSICAL JOURNAL J2 - BIOPHYS J VL - 118 PY - 2020 IS - 3 SP - 576A EP - 576A SN - 0006-3495 DO - 10.1016/j.bpj.2019.11.3130 UR - https://m2.mtmt.hu/api/publication/31179616 ID - 31179616 LA - English DB - MTMT ER - TY - JOUR AU - Lukács, Péter AU - Földi, Mátyás Csaba AU - Valanszki, L AU - Casanova, E AU - Biri-Kovács, Beáta AU - Nyitray, László AU - Málnási Csizmadia, András AU - Mike, Árpád TI - Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photoreactive riluzole analog JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 8 PY - 2018 PG - 11 SN - 2045-2322 DO - 10.1038/s41598-018-26444-y UR - https://m2.mtmt.hu/api/publication/3397475 ID - 3397475 N1 - MTA-ELTE NAP B Opto-Neuropharmacology Group Hungary, Budapest, Hungary Department of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary MTA-ELTE Molecular Biophysics Research Group, Eötvös Loránd University, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Martonvásár, Hungary Cited By :1 Export Date: 31 July 2019 Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology Group HungaryHungary; email: arpadmike1@gmail.com Funding details: Office of Research, Innovation and Economic Development, California State Polytechnic University, Pomona, VKSZ_14–1–2015–0052 Funding details: KTIA-NAP-13–2–2014–002 Funding text 1: This work was supported by the Hungarian Brain Research Program (KTIA-NAP-13–2–2014–002), and The National Research, Development and Innovation Office (VKSZ_14–1–2015–0052). Plasmid DNA for NaV1.4 channel were kindly provided by Hannes Todt. MTA-ELTE NAP B Opto-Neuropharmacology Group Hungary, Budapest, Hungary Department of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary MTA-ELTE Molecular Biophysics Research Group, Eötvös Loránd University, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Martonvásár, Hungary Cited By :1 Export Date: 10 August 2019 Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology Group HungaryHungary; email: arpadmike1@gmail.com Funding details: Office of Research, Innovation and Economic Development, California State Polytechnic University, Pomona, VKSZ_14–1–2015–0052 Funding details: KTIA-NAP-13–2–2014–002 Funding text 1: This work was supported by the Hungarian Brain Research Program (KTIA-NAP-13–2–2014–002), and The National Research, Development and Innovation Office (VKSZ_14–1–2015–0052). Plasmid DNA for NaV1.4 channel were kindly provided by Hannes Todt. MTA-ELTE NAP B Opto-Neuropharmacology Group Hungary, Budapest, Hungary Department of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary MTA-ELTE Molecular Biophysics Research Group, Eötvös Loránd University, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Martonvásár, Hungary Cited By :1 Export Date: 18 September 2019 Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology Group HungaryHungary; email: arpadmike1@gmail.com MTA-ELTE NAP B Opto-Neuropharmacology Group Hungary, Budapest, Hungary Department of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary MTA-ELTE Molecular Biophysics Research Group, Eötvös Loránd University, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Martonvásár, Hungary Cited By :2 Export Date: 11 February 2020 Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology Group HungaryHungary; email: arpadmike1@gmail.com MTA-ELTE NAP B Opto-Neuropharmacology Group Hungary, Budapest, Hungary Department of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary MTA-ELTE Molecular Biophysics Research Group, Eötvös Loránd University, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Martonvásár, Hungary Cited By :2 Export Date: 17 April 2020 Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology Group HungaryHungary; email: arpadmike1@gmail.com Chemicals/CAS: azide, 12596-60-0, 14343-69-2; riluzole, 1744-22-5; Azides; Muscle Proteins; Riluzole; Scn4a protein, rat; Sodium Channel Blockers; Sodium Channels Funding details: VKSZ_14–1–2015–0052 Funding details: KTIA-NAP-13–2–2014–002 Funding text 1: This work was supported by the Hungarian Brain Research Program (KTIA-NAP-13–2–2014–002), and The National Research, Development and Innovation Office (VKSZ_14–1–2015–0052). Plasmid DNA for NaV1.4 channel were kindly provided by Hannes Todt. MTA-ELTE NAP B Opto-Neuropharmacology Group Hungary, Budapest, Hungary Department of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary MTA-ELTE Molecular Biophysics Research Group, Eötvös Loránd University, Budapest, Hungary Plant Protection Institute, Centre for Agricultural Research, Hungarian Academy of Sciences, Martonvásár, Hungary Cited By :4 Export Date: 20 March 2021 Correspondence Address: Mike, A.; MTA-ELTE NAP B Opto-Neuropharmacology Group HungaryHungary; email: arpadmike1@gmail.com Chemicals/CAS: azide, 12596-60-0, 14343-69-2; riluzole, 1744-22-5; Azides; Muscle Proteins; Riluzole; Scn4a protein, rat; Sodium Channel Blockers; Sodium Channels Funding details: KTIA-NAP-13–2–2014–002 Funding details: VKSZ_14–1–2015–0052 Funding text 1: This work was supported by the Hungarian Brain Research Program (KTIA-NAP-13–2–2014–002), and The National Research, Development and Innovation Office (VKSZ_14–1–2015–0052). Plasmid DNA for NaV1.4 channel were kindly provided by Hannes Todt. AB - Sodium channel inhibitor drugs decrease pathological hyperactivity in various diseases including pain syndromes, myotonia, arrhythmias, nerve injuries and epilepsies. Inhibiting pathological but not physiological activity, however, is a major challenge in drug development. Sodium channel inhibitors exert their effects by a dual action: they obstruct ion flow ("block"), and they alter the energetics of channel opening and closing ("modulation"). Ideal drugs would be modulators without blocking effect, because modulation is inherently activity-dependent, therefore selective for pathological hyperactivity. Can block and modulation be separated? It has been difficult to tell, because the effect of modulation is obscured by conformation-dependent association/dissociation of the drug. To eliminate dynamic association/dissociation, we used a photoreactive riluzole analog which could be covalently bound to the channel; and found, unexpectedly, that drug-bound channels could still conduct ions, although with modulated gating. The finding that non-blocking modulation is possible, may open a novel avenue for drug development because non-blocking modulators could be more specific in treating hyperactivity-linked diseases. LA - English DB - MTMT ER -